AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $37.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $2K to $30K in total in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$37.5M netNet selling
- CongressSTOCK Act, last 180 days
- $2K to $30K tradedMixed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 2 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $186.55
- 52-wk high
- $208.90
- High
- $196.83
- 52-wk low
- $22.28
- Low
- $184.58
- Prev close
- $203.46
- Mkt cap
- $81.23B
- Volume
- 20.10M
- Fwd P/E
- 23.0x
- Beta
- 1.11
- P/S
- 36.5x
- P/B
- 10.8x
- Profit margin
- -141.4%
- Op margin
- -558.0%
- ROE
- -39.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about MRNA filings
Are insiders buying or selling Moderna Inc (MRNA) stock?
Net selling: insiders sold $37.5M and bought $0 of MRNA stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $37.5M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Bancel, Stephane (Chief Executive Officer), who sold $28.7M. The latest filing was on Sep 14, 2026.
Which members of Congress have traded MRNA recently?
Rep. Maria Elvira Salazar (R) sold $1K to $15K on Aug 19, 2026, disclosed 21 days later. Rep. Maria Elvira Salazar (R) bought $1K to $15K on Aug 19, 2026, disclosed 21 days later. In total, 1 member disclosed 2 MRNA trades with trade dates in the last 180 days, filed a median 21 days after trading.
How current is this MRNA smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position, insiders have been net selling, and 1 fin-fluencer is discussing it.
What funds are doing
Buys/Adds (2)
- BC
Baron Capital
$139.3M
bought
- AQ
AQR
$31.6M
added
Sells/Trims (1)
- DS
D.E. Shaw
$32.1M
trimmed
What insiders are doing
Sells (3)
- MJ
Mock James M
$4.7M
sold
- KS
Klinger Shannon Thyme
$486K
sold
- BS
Bancel Stephane
$28.7M
sold
What Congress is doing
Buys (1)
Sells (1)
How top traders are positioned
Activist stakes, short interest & more
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
-$1.97 expected
Revenue
No comparable estimate
Reports Oct 5, 2026, in 4 days
Estimates as of Sep 30, 2026
EPS expected
-$2.09 to -$0.63
Revenue expected
12 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.02B | $678.0M | $389.0M | $145.0M |
| Cost of what it sold | $1.01B | $452.0M | $955.0M | $93.0M |
| Gross profit | $8.0M | $226.0M | -$566.0M | $52.0M |
| What it spent | ||||
| Research and development | $801.0M | $775.0M | $649.0M | $651.0M |
| Sales and admin | $268.0M | $308.0M | $173.0M | $216.0M |
| Other operating costs | -$801.0M | — | — | — |
| Total operating expenses | $268.0M | $1.08B | $822.0M | $867.0M |
| What was left | ||||
| Operating profit | -$260.0M | -$857.0M | -$1.39B | -$815.0M |
| Interest on debt | $0 | $8.0M | $17.0M | $17.0M |
| Profit before tax | -$187.0M | -$799.0M | -$1.33B | -$767.0M |
| Tax | $13.0M | $27.0M | $9.0M | $15.0M |
| Net profit | -$200.0M | -$826.0M | -$1.34B | -$782.0M |
| EBITDA | -$135.0M | -$732.0M | -$1.26B | -$704.0M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Moderna stock hits 52-week high at 202.69 USD
Leans bullishSep 29Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Leans bullishSep 29Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE)
Leans bearishSep 28Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
NeutralSep 28Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?
NeutralSep 28Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
NeutralSep 28Why Did AMD, HPE, MRNA Stocks Surge To 52-Week Highs Last Week?
BullishSep 28Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?
NeutralSep 28
Macro
11 macro signals shaping MRNA right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results